TSH blood test
Thyroid-stimulating hormone. Also called: Thyrotropin, Thyroid-stimulating hormone, TSH, third generation
TSH is the pituitary hormone that tells the thyroid to make thyroid hormone. It is the single best screening test for thyroid problems: high TSH usually means an underactive thyroid, low TSH an overactive one or too much thyroid medicine.
Reported on the "with TSH" version of a standard Thyroid Panel. The panel page explains when free T4 and free T3 are added.
At a glance
| What it measures | Thyroid-stimulating hormone (thyrotropin), made by the pituitary to drive the thyroid. |
|---|---|
| Sample | Blood (serum preferred). Neither lab lists a fasting requirement, but TSH falls after a meal and later in the morning. |
| Typical adult range | Labcorp: 0.450-4.500 µIU/mL (over 10 years). Quest: 0.40-4.50 mIU/L (20 years and older), with lower pregnancy ranges. |
| Common reasons it reads high | Underactive thyroid (primary hypothyroidism), too little thyroid medicine, recovery from severe illness, older age and some drugs such as amiodarone. |
| Peptides that move it | Raised by Thyrotropin-Releasing Hormone (TRH). Lowered by Somatostatin, Octreotide and Lanreotide. No clinically significant change on Tesamorelin per its label. |
| Lab code | LOINC 3016-3 (Quest 899); 11580-8 third-generation (Labcorp 004259) |
What is TSH?
Thyroid-stimulating hormone (TSH, thyrotropin) is made by the pituitary gland and drives the thyroid to make thyroxine (T4). A serum TSH is the single best screening test for primary thyroid dysfunction in most outpatient situations.
Labcorp uses it to tell primary hypothyroidism (high TSH) from normal and from pituitary or hypothalamic causes, to screen for hyperthyroidism (low TSH), and to adjust thyroid hormone doses.
How it is made and regulated
Where it is made
Thyrotropin-releasing hormone (TRH) from the hypothalamus stimulates the pituitary to release TSH, which rises within 20-30 minutes of a TRH injection. Somatostatin from the hypothalamus does the opposite and suppresses it.
What controls it
TSH runs higher in the early morning than later in the day, rises with sleep deprivation, strenuous exercise and night shifts, and changes with the seasons. Repeated measurements in the same person vary considerably over months.
How it travels in the blood
Modern "third-generation" TSH assays can measure down to about 0.005 mU/L, two orders of magnitude more sensitive than the first radioimmunoassays. This is what allows a suppressed TSH to be told apart from a merely low one.
Sources: [9]
How long it lasts
We found no reliable half-life figure for TSH in the sources reviewed for this page. What matters for testing is its daily rhythm and its drop after meals.
What it does
TSH makes the thyroid produce thyroid hormone. When the thyroid fails (primary hypothyroidism) TSH rises; when the thyroid overproduces, or when thyroid medicine is excessive, TSH falls.
Sources: [2]
Reference ranges
Adult ranges are almost identical at the two labs. Infants and young children run higher, and pregnancy has its own, lower ranges by trimester. Where the adult upper limit should sit is debated (see below).
Labcorp (test 004259)
| Group | Range (mIU/L) |
|---|---|
| Over 10 years | 0.450-4.500 |
Children and teens
| Group | Range (mIU/L) |
|---|---|
| 0 to 6 days | 0.700-15.200 |
| 7 days to 3 months | 0.720-11.000 |
| 3 months 1 day to 12 months | 0.730-8.350 |
| 1 to 5 years | 0.700-5.970 |
| 6 to 10 years | 0.600-4.840 |
Printed in µIU/mL, numerically the same as mIU/L.
Quest Diagnostics (test 899)
| Group | Range (mIU/L) |
|---|---|
| 20 years and older | 0.40-4.50 |
| Pregnancy, first trimester | 0.26-2.66 |
| Pregnancy, second trimester | 0.55-2.73 |
| Pregnancy, third trimester | 0.43-2.91 |
Children and teens
| Group | Range (mIU/L) |
|---|---|
| Premature infants (28-36 weeks), first week | 0.20-27.90 |
| Term infants, serum or cord blood | 1.00-39.00 |
| 1-2 days | 3.20-34.60 |
| 3-4 days | 0.70-15.40 |
| 5 days-4 weeks | 1.70-9.10 |
| 1-11 months | 0.80-8.20 |
| 1-19 years | 0.50-4.30 |
Ranges as shown for Quest's East region. TSH falls quickly in the first week of life.
Labcorp reports µIU/mL, which is numerically the same as mIU/L. Labcorp's notes say guidelines recommend against routine treatment when TSH is 0.1-0.45 or 4.5-10.0, with repeat testing every 6 to 12 months. Quest's ranges are for its East region.
Units: Labcorp reports µIU/mL and Quest mIU/L; the two units are numerically the same. [2]
Is there an "optimal" range?
There is no agreed "optimal" TSH. Experts disagree about whether the upper limit should be lowered, and TSH rises naturally with age.
Lab reference ranges
Labcorp 0.45-4.50; Quest 0.40-4.50 mIU/L
Labcorp 004259 and Quest 899
The ranges labs print for adults; Labcorp notes guidelines recommend against routine treatment for TSH of 4.5-10.0 with repeat testing instead.
Narrow the upper limit to 2.5
Upper limit 2.5 mU/L
Wartofsky and Dickey (2005)
They cite National Academy of Clinical Biochemistry guidance that more than 95% of normal people have TSH below 2.5 mU/L, argue that older reference groups included people with hidden thyroid disease, and point to a mean of 1.18 mU/L in African Americans with little Hashimoto thyroiditis.
Sources: [12]
Keep the current range
Upper limit about 4.5 mIU/L
Surks and colleagues (2005)
Many people with TSH between 2.5 and 4.5 have no thyroid disease, and lowering the limit would label millions more Americans with subclinical hypothyroidism without evidence that treating them helps; checking TSH every 1-2 years is reasonable.
Sources: [7]
Use age-specific limits
97.5th centile 3.56 (age 20-29) to 7.49 mIU/L (80+)
Surks and Hollowell, NHANES (2007)
In people without thyroid disease the whole TSH distribution shifts upward with age; 70% of older people with TSH above 4.5 were within their age-specific range.
Sources: [13]
Treatment threshold
Treat at 10 or above; below 10, individualize
American Association of Clinical Endocrinologists and American Thyroid Association guideline (2012)
The decision to treat subclinical hypothyroidism when TSH is below 10 mIU/L should be tailored to the individual patient.
Sources: [1]
What raises it
| Factor | How | How much |
|---|---|---|
| Underactive thyroid (primary hypothyroidism)Condition | When the thyroid fails, the pituitary pushes out more TSH. | No published magnitude [2] [3] |
| Older agePhysiology | TSH rises with age even without thyroid disease. | 97.5th centile 3.56 mIU/L at 20-29 vs 7.49 at 80+ [13] [14] |
| Early-morning and fasting samplesPhysiology | TSH is higher early in the morning and in the fasting state, and falls after eating. | About 30% lower 2 hours after a meal than fasting [11] [15] [7] |
| Recovery from severe illnessCondition | TSH can be suppressed during severe illness and then rise during recovery. | No published magnitude [2] [16] |
| Some medicinesMedication | Amiodarone, iopanoic acid and ipodate raise TSH; lithium, interferon and newer cancer drugs can cause hypothyroidism. | No published magnitude [2] [17] |
| TRHPeptide | TRH stimulates TSH release directly. See the peptide table below. | Rise of 2.0 microunits/mL or more 30 minutes after TRH in 95% of euthyroid people (compounded TRH label) [5] |
What lowers it
| Factor | How | How much |
|---|---|---|
| Overactive thyroid or too much thyroid medicineCondition | Excess thyroid hormone switches off pituitary TSH. | No published magnitude [2] |
| Glucocorticoids, dopamine and severe illnessMedication | Labcorp lists these as affecting TSH, even with sensitive assays. | No published magnitude [2] [16] |
| Eating before the testNutrition | TSH falls after a meal; in one study 15 of 20 people classed as subclinically hypothyroid when fasting were within range after food. | About 30% lower 2 hours after a meal [11] [15] |
| High-dose biotin (false result)Nutrition | Biotin interferes with streptavidin-based assays and can give a falsely low TSH; Labcorp asks people to stop it at least 72 hours before the test. | No published magnitude [18] [2] |
| Somatostatin and its analogsPeptide | Somatostatin suppresses TSH; the octreotide label says it may cause hypothyroidism. See the peptide table below. | Somatostatin infusion: TSH nadir 65.0% of baseline in hypothyroid patients [6] [19] |
Peptides that affect TSH
How each peptide in our library has been shown to affect TSH, strongest evidence first. TRH raises TSH; somatostatin and its analogs lower it; most GH-releasing peptides have little effect. "No clear effect" means TSH was measured and did not change; "Unclear" means the results conflict.
| Peptide | Effect on TSH | Size of effect | Evidence |
|---|---|---|---|
| MK-677 (Ibutamoren) | Raises | 24 obese men, MK-677 25 mg/day vs placebo for 8 weeks (sustained): mean peak TSH higher at 8 weeks (P < 0.05) but within the normal range; no change at 2 weeksA small TSH rise after 8 weeks that stayed within the normal range. [20] | Human trials |
| Thyrotropin-Releasing Hormone (TRH) | Raises | Acute single dose. IV TRH 50 micrograms or more raised serum TSH, peaking at 20 minutes; oral TRH 1 mg and above raised TSH, maximal at two hours. TRH 500 mcg product label: 30 minutes after TRH, TSH rose by 2.0 microunits/mL or more in 95% of euthyroid subjectsTRH reliably raises TSH within 20-30 minutes; this is the basis of the TRH stimulation test. The product label cited is a compounding pharmacy's listing on DailyMed, not an FDA-approved drug label. [4] [5] | Human trials |
| Adrenocorticotropic Hormone (ACTH) | Lowers | Single IM dose of synthetic ACTH 1 mg in 38 hospitalized patients with acute gout and normal thyroid function (32 analysed): serum TSH and T4 significantly decreased at 24 and 48 h vs baseline (acute)A single large dose of ACTH lowered TSH for at least 48 hours, more than betamethasone did. Not studied with ongoing use. [21] | Human trials |
| Exenatide | Lowers | Type 2 diabetes without thyroid disease (46 enrolled, 13 excluded), 6 months: TSH 2.3 to 1.8 mIU/L (p = 0.007), free T4 unchanged. 112 people with type 2 diabetes and obesity, 12 months: TSH change -0.25 mU/L (-0.43 to -0.06), linked to weight lossTSH fell modestly on exenatide, with free T4 unchanged; the fall tracked weight loss. Uncontrolled cohort studies. [22] [23] | Human trials |
| GHRP-6 | Lowers | Nine healthy young men, 34-h IV GHRP-6 infusion (1 microgram/kg loading bolus, then 1 microgram/kg.h; sustained) vs saline: baseline TSH lower and the TSH response to a 50-microgram TRH bolus smaller; no values in the abstractA day-and-a-half infusion slightly lowered TSH in healthy men. No data on usual injection schedules. [24] | Human trials |
| Liraglutide | Lowers | 49 overweight or obese adults with type 2 diabetes, liraglutide for an average of 16 months (sustained, before-after, no placebo group): TSH lower than baseline (p < 0.05), alongside lower BMI and HbA1c; no values in the abstractTSH fell in one uncontrolled study, along with weight; weight loss itself may explain it. [25] | Human trials |
| Macimorelin | Lowers | 28 healthy volunteers, single oral dose 0.5 and 0.75 mg/kg (acute), sampled to 120 min: TSH -0.18 mU/L (p < 0.001) while free T4 roseA small, short-lived TSH dip after the diagnostic dose. No repeated-dosing data. [26] | Human trials |
| Somatostatin | Lowers | 8 patients with primary hypothyroidism, somatostatin 1000 micrograms IV over 105 min (acute): TSH suppressed to 42.6-76.9% of pre-infusion levels, mean nadir 65.0 ± 4.0%A somatostatin infusion lowered TSH within two hours in people with high TSH from primary hypothyroidism. [6] | Human trials |
| Calcitonin | No clear effect | Single 50 MRCU dose of synthetic salmon calcitonin in 14 healthy volunteers (acute): basal TSH declined insignificantly at 60 min; TRH-stimulated TSH was significantly lower than control (p less than 0.01)Resting TSH did not change significantly; only the TSH response to a TRH stimulation test was blunted. [27] | Human trials |
| GHRH (1-44) | No clear effect | Six healthy men given GHRH (GRF) 0.05, 0.1 or 1 microgram/kg IV (acute): plasma TSH did not change at any doseGHRH did not change TSH in healthy men. [28] | Human trials |
| Hexarelin | No clear effect | Seven healthy adults (4 women, 3 men), hexarelin 1 microgram/kg IV (acute): serum TSH unmodified; TRH-stimulated TSH 1124 ± 530 with hexarelin vs 1273 ± 380 mU/min/l with placeboA single dose did not change TSH or the TSH response to TRH. [29] | Human trials |
| Leptin | No clear effect | 24 overweight and obese adults on a mild hypocaloric diet, metreleptin 10 mg/day s.c. vs placebo for 6 months (sustained): TSH unchanged in both groups, no between-group differenceSix months of leptin did not change TSH during diet-induced weight loss. [30] | Human trials |
| Sermorelin | No clear effect | Five normal men, single IV bolus of GHRH(1-29)-NH2 (sermorelin) 0.015 to 0.5 micrograms/kg (acute): TSH unchanged, as were PRL, LH, FSH and ACTHA single dose of sermorelin did not change TSH or other pituitary hormones in healthy men. Small study, single dose. [31] | Human trials |
| Ghrelin | Unclear | 20 healthy adults, ghrelin 50 micrograms at 2200, 2300, 0000 and 0100 h (crossover): TSH lower from 0200 h (AUC 1.32 vs 1.74 with placebo, P = 0.007), free T4 slightly higher. Obese women with and without PCOS, ghrelin 1 microg/kg: TSH not changed (acute)Overnight ghrelin lowered TSH in one study but a single daytime dose did not change it in another. [32] [33] | Human trials |
| GHRP-2 | Unclear | Prolonged critical illness, continuous IV GHRP-2 1 microg/kg/h overnight (sustained infusion): synchronized TSH release with GH and PRL (P ≤ 0.007), but in a separate study only TRH + GHRP-2, not GHRP-2 alone, increased pulsatile TSH secretion (4-fold)In critically ill patients GHRP-2 changed the timing of TSH release; a rise in TSH needed TRH as well. No data in healthy people. [34] [35] | Human trials |
| Semaglutide | Unclear | Retrospective single-center chart review, 255 adults on semaglutide for weight management: TSH higher after treatment (no control group, no values in the abstract). A systematic review of GLP-1 receptor agonists found only one study that directly assessed thyroid function testsOne uncontrolled chart review found a TSH rise; randomized trials have not reported TSH. Too little data to call. [36] [37] | Human trials |
| Lanreotide | Lowers | Label: lanreotide inhibits the nocturnal TSH rise in healthy subjects; in acromegaly, slight decreases in thyroid function, with clinical hypothyroidism in less than 1%Somatostatin blunts the night-time TSH rise. Real hypothyroidism is rare (under 1%). [38] | FDA label |
| Octreotide | Lowers | Sandostatin label: "Octreotide suppresses secretion of thyroid stimulating hormone (TSH), which may result in hypothyroidism." In acromegaly, biochemical hypothyroidism alone occurred in 12%, goiter in 8%, and 4% needed thyroid replacement during therapy (sustained dosing)Suppresses TSH; the label advises baseline and periodic thyroid tests during long-term use. [19] | FDA label |
| Tesamorelin | No clear effect | Egrifta SV label, verbatim: "No clinically significant changes in the levels of other pituitary hormones, including thyroid-stimulating hormone (TSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH) and prolactin, were observed in patients receiving EGRIFTA in clinical trials." (sustained daily dosing; values not given)The label names TSH among pituitary hormones that did not change meaningfully in the clinical trials. [39] | FDA label |
| Pasireotide | Unclear | Signifor label: "inhibition of pituitary hormones, other than ACTH, may occur", with TSH/free T4 monitoring advised. Hypothyroidism was reported in seven patients in the phase III Cushing's disease study, but all had TSH close to or below the lower limit at study entry, "which precludes establishing a conclusive relationship" (sustained dosing)The label warns that other pituitary hormones, including TSH, may be suppressed, but its trial data could not link hypothyroidism to the drug. [40] | FDA label |
| Irisin | Raises | Sprague-Dawley rats on paroxetine, irisin 100 ng/kg/day for 28 days by s.c. osmotic pump (sustained): restored the paroxetine-lowered TSH and free T4 in males; the rise in females was not significantOnly shown in rats whose thyroid hormones had been lowered by an antidepressant. No human data. [41] | Animal studies |
| Thymalin | Raises | Rats with an intact immune system given thymalin: serum TSH ("TTH") increased while total T3 and T4 fell, with hyperplastic thyroid epithelium. No values in the abstractOne 1991 rat abstract, with no values; not studied in people. [42] | Animal studies |
| MOTS-c | Lowers | Serum TSH (ELISA), male Wistar Albino rats given intracerebroventricular MOTS-c at 10 or 100 µM (10 rats per group): TSH, T3 and T4 all decreased; no values in the abstractLowered TSH and thyroid hormones in rats when infused into the brain. No human data. [43] | Animal studies |
| Ipamorelin | No clear effect | Conscious swine (pigs), acute doses of ipamorelin, GHRP-6 and GHRP-2: plasma TSH (and FSH, LH, PRL) unchangedIpamorelin did not change TSH in pigs. No human data. [44] | Animal studies |
| Neurotensin | No clear effect | Female rats, neurotensin 2 micrograms/rat/day i.p. for 7 days: serum TSH unchanged (serum T4 fell)TSH did not change in rats, although T4 fell. No human data. [45] | Animal studies |
| Dynorphin | Unclear | Rats, dynorphin (1-13) 500 micrograms/kg IV: basal plasma TSH fell, nadir at 40 min. Ovariectomized rhesus monkeys, dynorphin-(1-13) 30-120 micrograms/kg IV: no significant effect on TSH (acute)Lowered TSH in rats but not in monkeys. No human data. [46] [47] | Animal studies |
| Neuropeptide Y | Unclear | Female rats, NPY 0.5 microgram i.p. twice a day for 4 days: serum TSH unchanged. Lizards (Podarcis siculus): dose-dependent fall in plasma TSH 2 and 24 h after NPY. No human dataNo TSH change in rats, a fall in lizards. No human data. [45] [48] | Animal studies |
What high or low results can mean
A high result
A high TSH usually means the thyroid is underactive. With a normal free T4 it is called subclinical hypothyroidism; with a low free T4, overt hypothyroidism.
- Primary hypothyroidism, often Hashimoto thyroiditis
- Too little thyroid medicine
- Older age
- Recovery from severe illness
- Drugs such as amiodarone or lithium
- Early-morning fasting sample
A low result
A low TSH usually means too much thyroid hormone, from an overactive thyroid or from medicine. With normal free T4 and T3 it is subclinical hyperthyroidism.
- Hyperthyroidism (Graves disease, toxic nodules)
- Too much thyroid medicine
- Severe illness
- Glucocorticoids or dopamine
- High-dose biotin (falsely low)
How the test works
| Sample | Labcorp prefers serum (red-top, gel-barrier or lithium-heparin tube; not oxalate, EDTA or citrate). Quest asks for 1 mL of serum, and delays testing for at least 3 days after fluorescein angiography and 2 weeks for people on hemodialysis. |
|---|---|
| Fasting | Neither Labcorp nor Quest lists a fasting requirement, but TSH is about 30% lower 2 hours after a meal, so testing at the same time and fasting state each time helps. |
| Timing | TSH is higher in the early morning than later in the day: in one study, results at 7-8 a.m. averaged 2.50 mIU/L vs 1.74 mIU/L 140 minutes later, still fasting. Stop high-dose biotin at least 72 hours before. |
| Lab differences | Labcorp uses an ECLIA (reported as a third-generation code, LOINC 11580-8) and Quest an immunoassay. Antibodies against animal (bovine) TSH can give a spuriously high result, and fluorescein can give a falsely low one with some assays. |
| Retesting | TSH varies a lot within a person: a change of more than about 54.7% between two results was needed to be meaningful in healthy European adults. |
| Labcorp order code | 004259: Thyroid-stimulating Hormone (TSH) |
| Quest Diagnostics order code | 899: TSH |
| LOINC codes |
|
History
TSH went from a research measurement to the first-line thyroid test as assays became sensitive enough to measure low values reliably.
- 1965Utiger publishes a radioimmunoassay of human plasma thyrotropin. [52]
- 1970The structure of thyrotropin-releasing hormone (TRH), the hypothalamic hormone that drives TSH, is reported. [53]
- 1990Spencer and colleagues describe the first "third-generation" TSH assay, sensitive to about 0.005 mU/L. [9]
- 2002NHANES III reports TSH and thyroid antibodies in 17,353 Americans, the basis of later reference-range debates. [14]
- 2005Paired articles argue for and against narrowing the TSH upper limit to 2.5 mU/L. [12] [7]
- 2007Surks and Hollowell show the TSH distribution shifts higher with age and propose age-specific ranges. [13]
- 2012The AACE and ATA hypothyroidism guideline names serum TSH the single best screening test. [1]
FAQ
What is a normal TSH level?
For adults, about 0.4-4.5 mIU/L: Labcorp 0.450-4.500 µIU/mL and Quest 0.40-4.50 mIU/L. Pregnancy ranges are lower, and older adults naturally run higher.
Should my TSH be below 2.5?
That is debated. Wartofsky and Dickey argued that more than 95% of normal people are below 2.5, while Surks and colleagues argued that lowering the limit would label millions without evidence that treatment helps. No guideline sets 2.5 as a treatment target for non-pregnant adults.
Does TSH increase with age?
Yes. In people without thyroid disease, the 97.5th centile rose from 3.56 mIU/L at 20-29 to 7.49 at 80 and over, and 70% of older people with TSH above 4.5 were within their age-specific range.
Sources: [13]
Do I need to fast for a TSH test?
Neither lab requires it, but TSH was about 30% lower 2 hours after a meal than fasting, enough to change a borderline result. Test at the same time and in the same fasting state each time.
Does the time of day matter?
Yes. TSH is higher in the early morning; in one study results at 7-8 a.m. averaged 2.50 mIU/L vs 1.74 mIU/L 140 minutes later, without eating.
What is subclinical hypothyroidism?
A TSH above the range with a normal free T4. Treatment is generally recommended when TSH is 10 mIU/L or higher; below that it is an individual decision, and many people are just retested.
Can biotin affect my TSH?
Yes. High-dose biotin interferes with streptavidin-based assays and can make thyroid tests look like an overactive thyroid. Labcorp asks people to stop biotin at least 72 hours before the test.
What TSH is right in pregnancy?
Quest uses trimester ranges of 0.26-2.66 (first), 0.55-2.73 (second) and 0.43-2.91 mIU/L (third). The American Thyroid Association publishes separate guidance for thyroid disease in pregnancy.
How much does TSH vary between tests?
A lot. In healthy adults a change of more than about 54.7% was needed before it was likely to be real, and TSH also shifts with season and over months.
Do GH peptides change TSH?
Mostly not meaningfully. The Egrifta SV label reports no clinically significant change in TSH with Tesamorelin; Sermorelin and Hexarelin showed no clear effect in small studies, and MK-677 (Ibutamoren) raised peak TSH slightly within the normal range after 8 weeks.
Which peptides lower TSH?
Somatostatin and its analogs: a somatostatin infusion lowered TSH within 2 hours, and the Octreotide label says it suppresses TSH and may cause hypothyroidism. Lanreotide blunts the night-time TSH rise.
What does TRH do to TSH?
Thyrotropin-Releasing Hormone (TRH) raises it within 20-30 minutes, which is the basis of the TRH stimulation test. The product label we cite is a compounding pharmacy's DailyMed listing, not an FDA-approved label.
References
- Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18(6):988-1028. PMID 23246686
- Labcorp. Test 004259: Thyroid-stimulating Hormone (TSH). Use, special instructions, limitations, additional information, specimen requirements, reference range and LOINC map. labcorp.com/tests/004259/thyroid-stimulating-hormone-tsh
- Quest Diagnostics. Test code 899: TSH. Test directory entry (East region): methodology, specimen, patient preparation, reference ranges (including pregnancy) and LOINC. testdirectory.questdiagnostics.com/test/test-detail/899/tsh?cc=PHP
- Ormston BJ, Kilborn JR, Garry R, et al. Further observations on the effect of synthetic thyrotropin-releasing hormone in man. Br Med J. 1971;2(5755):199-202. PMID 4102606
- Thyrotropin Releasing Hormone (TRH) solution, AnazaoHealth compounded-product label (not an FDA-approved drug label). DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af5da799-76bf-415a-9dc7-99c7ddc62bc4
- Lucke C, Höffken B, von zur Mühlen A. The effect of somatostatin on TSH levels in patients with primary hypothyroidism. J Clin Endocrinol Metab. 1975;41(06):1082-4. PMID 1206095
- Surks MI, Goswami G, Daniels GH. The thyrotropin reference range should remain unchanged. J Clin Endocrinol Metab. 2005;90(9):5489-96. PMID 16148346
- van der Spoel E, Roelfsema F, van Heemst D. Within-Person Variation in Serum Thyrotropin Concentrations: Main Sources, Potential Underlying Biological Mechanisms, and Clinical Implications. Front Endocrinol (Lausanne). 2021;12:619568. PMID 33716972
- Spencer CA, LoPresti JS, Patel A, et al. Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. J Clin Endocrinol Metab. 1990;70(2):453-60. PMID 2105333
- Mirjanic-Azaric B, Stojakovic-Jelisavac T, Vukovic B, et al. The impact of time of sample collection on the measurement of thyroid stimulating hormone values in the serum. Clin Biochem. 2015;48(18):1347-9. PMID 26297800
- Dong A, Huang Y, Huang Y, et al. Effects of calorie intake and sampling time on thyroid stimulating hormone concentration. BMC Endocr Disord. 2022;22(1):85. PMID 35365148
- Wartofsky L, Dickey RA. The evidence for a narrower thyrotropin reference range is compelling. J Clin Endocrinol Metab. 2005;90(9):5483-8. PMID 16148345
- Surks MI, Hollowell JG. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab. 2007;92(12):4575-82. PMID 17911171
- Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489-99. PMID 11836274
- Nair R, Mahadevan S, Muralidharan RS, et al. Does fasting or postprandial state affect thyroid function testing?. Indian J Endocrinol Metab. 2014;18(5):705-7. PMID 25285290
- Chopra IJ. Nonthyroidal illness syndrome or euthyroid sick syndrome?. Endocr Pract. 1996;2(1):45-52. PMID 15251561
- Rizzo LFL, Mana DL, Serra HA. Drug-induced hypothyroidism. Medicina (B Aires). 2017;77(5):394-404. PMID 29044016
- Ardabilygazir A, Afshariyamchlou S, Mir D, et al. Effect of High-dose Biotin on Thyroid Function Tests: Case Report and Literature Review. Cureus. 2018;10(6):e2845. PMID 30140596
- SANDOSTATIN (octreotide acetate) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e2c9856-1836-49f0-9472-4dbeeb408f39
- Svensson J, Carlsson B, Carlsson LM, et al. Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK-677. Clin Endocrinol (Oxf). 1999;50(4):451-6. PMID 10468903
- Markantes GK, Daoussis D, Mamali I, et al. Differences in thyroid function tests after administration of a single supraphysiological dose of ACTH or a high dose of a synthetic steroid. Steroids. 2022;182:109009. PMID 35283116
- Sencar ME, Sakiz D, Calapkulu M, et al. The Effect of Exenatide on Thyroid-Stimulating Hormone and Thyroid Volume. Eur Thyroid J. 2019;8(6):307-311. PMID 31934556
- Tee SA, Tsatlidis V, Razvi S. The GLP-1 receptor agonist exenatide reduces serum TSH by its effect on body weight in people with type 2 diabetes. Clin Endocrinol (Oxf). 2023;99(4):401-408. PMID 36843143
- Jaffe CA, Ho PJ, Demott-Friberg R, et al. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. J Clin Endocrinol Metab. 1993;77(6):1641-7. PMID 7903313
- Ye J, Xu J, Wen W, et al. Effect of Liraglutide on Serum TSH Levels in Patients with NAFLD and its Underlying Mechanisms. Int J Clin Pract. 2022;2022:1786559. PMID 36311486
- Urwyler SA, Lustenberger S, Drummond JR, et al. Effects of oral macimorelin on copeptin and anterior pituitary hormones in healthy volunteers. Pituitary. 2021;24(4):555-563. PMID 33615399
- Zofková I, Bednár J. Calcitonin inhibits TRH-induced TSH secretion. Exp Clin Endocrinol. 1984;83(3):263-8. PMID 6432564
- Zanoboni A, Gibillini M, Cucchi MR, et al. Inhibitory influence of thyrotropin releasing hormone administration on growth hormone response to low doses of growth hormone-releasing hormone in normal man. J Endocrinol Invest. 1988;11(6):413-7. PMID 3145297
- Arosio M, Casati G, Biella O, et al. Lack of effect of hexarelin on TRH-induced TSH response in normal adult man. J Endocrinol Invest. 1998;21(4):239-44. PMID 9624598
- Shetty GK, Matarese G, Magkos F, et al. Leptin administration to overweight and obese subjects for 6 months increases free leptin concentrations but does not alter circulating hormones of the thyroid and IGF axes during weight loss induced by a mild hypocaloric diet. Eur J Endocrinol. 2011;165(2):249-54. PMID 21602313
- Barron JL, Coy DH, Millar RP. Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men. Peptides. 1985;6(3):575-7. PMID 2866496
- Kluge M, Riedl S, Uhr M, et al. Ghrelin affects the hypothalamus-pituitary-thyroid axis in humans by increasing free thyroxine and decreasing TSH in plasma. Eur J Endocrinol. 2010;162(6):1059-65. PMID 20423986
- Fusco A, Bianchi A, Mancini A, et al. Effects of ghrelin administration on endocrine and metabolic parameters in obese women with polycystic ovary syndrome. J Endocrinol Invest. 2007;30(11):948-56. PMID 18250617
- Van den Berghe G, Wouters P, Bowers CY, et al. Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness. Eur J Endocrinol. 1999;140(1):17-22. PMID 10037246
- Van den Berghe G, de Zegher F, Baxter RC, et al. Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. J Clin Endocrinol Metab. 1998;83(2):309-19. PMID 9467533
- Dayel FFB, Alanazi RJ, Alenazi MA, et al. Impact of Semaglutide as Weight Management Medication on Clinical Parameters and Health-Related Quality of Life: A Single-Center Study from Saudi Arabia. Healthcare (Basel). 2026;14(7). PMID 41975849
- Salama S, Elfaki Omer EO, Mahmoud A, et al. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Thyroid Function Tests: A Systematic Review Identifying a Critical Evidence Gap. Cureus. 2026;18(4):e108005. PMID 42220875
- SOMATULINE DEPOT (lanreotide) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e4a41fd-a753-4362-87ee-8cc56ed3660d
- EGRIFTA SV (tesamorelin for injection), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- SIGNIFOR (pasireotide) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a09a25fc-a5a3-0c82-e053-2995a90a5d74
- Ercan Z, Dogru MS, Ertugrul NU, et al. The Effect of Irisin on Thyroid Hormone Levels in Chronic Paroxetine-Treated Rats. Biol Trace Elem Res. 2023;201(2):810-815. PMID 35322355
- Khmel'nitskiĭ OK, Brezhneva VA. [Functional morphology of peripheral endocrine glands after thymic polypeptide administration in secondary immunodeficiency]. Arkh Patol. 1991;53(1):9-13. PMID 1859290
- Bahar MR, Tekin S, Beytur A, et al. Effects of intracerebroventricular MOTS-c infusion on thyroid hormones and uncoupling proteins. Biol Futur. 2023;74(1-2):159-170. PMID 37067760
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PMID 9849822
- Malendowicz LK, Miśkowiak B. Effects of prolonged administration of neurotensin, arginine-vasopressin, NPY, and bombesin on blood TSH, T3 and T4 levels in the rat. In Vivo. 1990;4(4):259-61. PMID 2103370
- Mitsuma T, Nogimori T. Dynorphin (1-13) effects on thyrotrophin-releasing hormone and thyrotrophin secretion in rats. Acta Endocrinol (Copenh). 1983;103(3):359-64. PMID 6410639
- Gilbeau PM, Hosobuchi Y, Lee NM. Dynorphin effects on plasma concentrations of anterior pituitary hormones in the nonhuman primate. J Pharmacol Exp Ther. 1986;238(3):974-7. PMID 2875176
- Sciarrillo R, Lallo A, Carrella F, et al. Thyroid Response to Peripheral Endocrine Factors: Neuropeptide Y Influences Thyroid Function in the Reptile Podarcis siculus. Int J Mol Sci. 2025;26(23). PMID 41373667
- Biondi B, Bartalena L, Cooper DS, et al. The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. Eur Thyroid J. 2015;4(3):149-63. PMID 26558232
- LOINC 3016-3: Thyrotropin [Units/volume] in Serum or Plasma. Regenstrief Institute. Record checked through the NLM Clinical Table Search Service. loinc.org/3016-3
- Mairesse A, Wauthier L, Courcelles L, et al. Biological variation and analytical goals of four thyroid function biomarkers in healthy European volunteers. Clin Endocrinol (Oxf). 2021;94(5):845-850. PMID 33107075
- UTIGER RD. RADIOIMMUNOASSAY OF HUMAN PLASMA THYROTROPIN. J Clin Invest. 1965;44(8):1277-86. PMID 14322035
- Nair RM, Barrett JF, Bowers CY, et al. Structure of porcine thyrotropin releasing hormone. Biochemistry. 1970;9(5):1103-6. PMID 4984938
- Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27(3):315-389. PMID 28056690
Educational information, not medical advice. Lab ranges and test codes were checked on October 30, 2026. Always use the range printed on your own report, and talk to a clinician about your results.